Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | CASP1 | P29466 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364156 | 1.00 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTPOLBNPC1 | |
| SCHEMBL240893 | 0.85 | ALDH1A1 (0.38) | ALDH1A1KDM4EMAPTCYP3A4ATM | |
| Quinoline SCHEMBL28190534 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTPOLBNPC1 | |
| Bromide SCHEMBL7758538 | 0.83 | ALDH1A1 (0.37) | ALDH1A1KDM4EATMHTTLMNA | |
| Quinoxaline SCHEMBL5268892 | 0.82 | ALDH1A1 (0.35) | ALDH1A1KDM4EMAPTPOLBATM | |
| SCHEMBL9901887 | 0.80 | NPC1 (0.43) | ALDH1A1KDM4EMAPTPOLBNPC1 | |
| SCHEMBL28809132 | 0.75 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTPOLBNPC1 | |
| SCHEMBL13403464 | 0.75 | HDAC8 (0.43) | ALDH1A1KDM4EMAPTPOLBNPC1 | |
| SCHEMBL4140452 | 0.75 | CYP1A2 (0.48) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL7900240 | 0.74 | HTT (0.42) | ALDH1A1KDM4EMAPTPOLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 791 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025316-A | Compound for targeted degradation of ALK protein, and preparation method and application thereof | 成都分迪药业有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-116509854-B | Application of naphthyridinone derivative | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 2025-05-23 | — | — | CN | claimed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | claimed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | claimed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| US-20240140944-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2024-05-02 | — | — | US | claimed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117209495-A | Tetrahydrodibenzo [ b, g ] [1,8] naphthyridine-1-ketone compound and preparation method and application thereof | 赣南师范大学 | 2023-12-12 | — | — | CN | claimed |
| US-6127363-A | FOR TRANSURETHRAL OR TRANSDERMAL ADMINISTRATION OR INTRACAVERNOSAL INJECTION, KITS | VIVUS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| US-5939550-A | Process for preparing derivatives of azabicyclo naphthyridine carboxylic acid comprising a dipeptide | PFIZER INC. (US) | 1999-08-17 | — | — | US | claimed |
| EP-0833837-A1 | PROCESS FOR PREPARING DERIVATIVES OF AZABICYCLO NAPHTHYRIDINE CARBOXYLIC ACID COMPRISING A DIPEPTIDE | PFIZER INC. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997000268-A1 | PROCESS FOR PREPARING DERIVATIVES OF AZABICYCLO NAPHTHYRIDINE CARBOXYLIC ACID COMPRISING A DIPEPTIDE | PFIZER INC. (US) | 1997-01-03 | — | — | WO | claimed |
| EP-0406112-B1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | claimed |
| EP-0228416-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES | SCHERING CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0133530-B1 | 1,6-NAPHTHYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND MEDICAMENTS CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-03-15 | — | — | EP | claimed |
| EP-0228416-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES. | SCHERING CORP (US) | 1987-07-15 | — | — | EP | claimed |
| WO-1986007537-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES | SCHERING CORPORATION (US) | 1986-12-31 | — | — | WO | claimed |
| EP-0127135-A2 | Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones | SCHERING CORPORATION (US) | 1984-12-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | ALDH1A1 4342/4885KDM4E 4298/4885MAPT 1/4885 |
| US-20240140944-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF | ENPP1, ENPP3, ENTPD5 | ALDH1A1 1224/4885KDM4E 3163/4885MAPT 3826/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | ALDH1A1 4385/4885KDM4E 4814/4885MAPT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.